Stock markets responded positively to the latest developments in presidential election. On the heels of the Dow Jones Industrial Average achieving a
Alexion Pharmaceuticals Inc.
-(ALXN)
XNAS:ALXN
Alexion’s long-term prospects remain intact amid continued focus on rare diseases
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has stood out in the crowded pharmaceuticals marketplace by developing effective treatments for certain rare health conditions. The
Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q1 2020 Earnings Call Transcript
Alexion Pharmaceuticals Inc (ALXN) Q1 2020 earnings call dated May. 06, 2020 Corporate Participants: Chris Stevo -- Head of Investor Relations Ludwig Hantson -- Chief Executive
Alexion Pharmaceuticals (ALXN) Q1 profit drops 5% but beats estimates
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens.
Alexion (ALXN) to acquire Portola (PTLA) for $1.44 billion
Alexion Pharmaceuticals (NASDAQ: ALXN) announced today that it will be acquiring commercial-stage biopharmaceutical company Portola Pharmaceuticals (NASDAQ: PTLA) for an initial consideration
Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q4 2019 Earnings Call Transcript
Alexion Pharmaceuticals Inc (NASDAQ: ALXN) Q4 2019 Earnings Conference Call January 30, 2020 Corporate Participants: Morgan Sanford -- Director of Investor Relations Ludwig Hantson -- Chief Executive
Alexion Pharmaceuticals, (ALXN): Q3 2019 Earnings Snapshot
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected. Revenues grew 23% to
Alexion Pharmaceuticals could still be a valuable addition to your portfolio
Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be the takeover
4 biotech stocks that are ideal takeover targets
Speculation plays a big role when investing in biotech stocks, hence making them highly volatile. It could be after years of stock
Earnings: Alexion Pharma Q2 results top expectations; raises FY19 guidance
Alexion Pharmaceuticals (Nasdaq: ALXN) reported a 28% growth for its second-quarter earnings, helped by an increase in revenues. The results also topped
Alexion Pharma stock jumps after Q4 results top expectations
Benefitting from the continued sales growth across all markets, led by cancer drug Soliris, Alexion Pharma (ALXN) Monday reported a double-digit increase
Earnings Preview: Soliris to drive Alexion’s Q4 topline
Alexion Pharmaceuticals Inc. (ALXN) is set to report fourth-quarter 2018 earnings results on Monday, February 4, before market open. Wall Street expects